Italia markets close in 4 hours 22 minutes
  • TikTok Downplays Chinese Communist Party Links in Australia Hearing
    Bloomberg

    TikTok Downplays Chinese Communist Party Links in Australia Hearing

    (Bloomberg) -- TikTok executives sought to reassure Australian lawmakers on Friday about the security of the app’s data and indicated the reported political affiliations of employees of Chinese parent ByteDance shouldn’t be a concern.Lee Hunter, general manager of TikTok Australia and New Zealand, told a parliamentary hearing that the app didn’t share the data of Australian users with the government in Beijing. Asked about reports that among ByteDance senior management, 130 were members of the Chinese Communist Party, Hunter said the “political affiliation of any employees does not impact the security of Australian user data.”While Australia in August ruled the video-sharing app doesn’t pose serious national security concerns and opted against a ban, a panel of lawmakers examining possible political interference through social media called on TikTok to testify.In a submission letter to the hearing, Hunter said personal data collected from Australian users is stored on servers located in the U.S. and Singapore.“We have strict controls around security and data access,” the letter dated Sept. 18 said. “TikTok has never shared Australian user data with the Chinese government, nor censored Australian content at its request.”Both TikTok and WeChat, which is owned by China’s Tencent Holdings Ltd., have been labeled national security threats by the Trump administration. The White House is looking to force a sale of TikTok to U.S. companies on the grounds the app could allow China’s government to gain access to personal data from millions of Americans.Hunter was asked by Senator Nick McKim if he considered TikTok to be bound by articles in China’s national intelligence law that requires intelligence cooperation. Hunter said he wasn’t familiar with the articles, adding “we do not share with the Chinese government.”TikTok says teams that moderate content on the app are based across 20 countries, and none are in China. Australia’s moderators are based in the Philippines and the U.K, Hunter said.When asked about content moderation in regards to Uighur Muslims, he said searching those terms on the social network would produce a wide range of content. TikTok controversially suspended one user last year who was critical of the Chinese government’s actions in Xinjiang.TikTok will likely be called back to testify to the Australian hearing again before the end of the year.(Corrects to show Hunter was responding to an assertion of CCP membership among senior ByteDance management)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • China Dairy Products News Service - ResearchAndMarkets.com
    Business Wire

    China Dairy Products News Service - ResearchAndMarkets.com

    The "Dairy Products China News" newsletter has been added to ResearchAndMarkets.com's offering.

  • GlobeNewswire

    uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

    ~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment; No Significant Safety Concerns Observed to Prevent Further Dosing ~LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease has met and reviewed 90-day safety data from the first two patients enrolled in the trial. No significant safety concerns were noted to prevent further dosing, and the next two patients are now cleared for enrollment in the study. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States. One patient has been treated with AMT-130, and one patient received the imitation surgery. “We are very pleased with the positive outcome from this first DSMB meeting,” said Ricardo Dolmetsch, president of research and development at uniQure. “We will now advance the study and expect to enroll the next two patients as soon as possible.”About the Phase I/II Clinical Trial of AMT-130The Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease will explore the safety, tolerability, and efficacy signals in 26 patients with early manifest Huntington’s disease randomized to treatment with AMT-130 or an imitation (sham) surgery. The five-year, multi-center trial consists of a blinded 12-month core study period followed by unblinded long-term follow-up. Patients will receive a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen). Additional details are available on www.clinicaltrials.gov (NCT04120493).AMT-130 is uniQure’s first clinical program focusing on the central nervous system (CNS) incorporating its proprietary miQURE™ platform.About Huntington’s Disease Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, and behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Despite the clear etiology of Huntington’s disease, there are no currently approved therapies to delay the onset or to slow the disease’s progression.About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.comuniQure Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, whether we will be able to enroll the next two patients in the clinical trial. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with the impact of the ongoing COVID-19 pandemic on our Company and the wider economy and health care system, our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s periodic securities filings, including its Annual Report on Form 10-K filed March 2, 2020 and Quarterly Report on Form 10-Q filed on July 30, 2020. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.uniQure Contacts:FOR INVESTORS:      FOR MEDIA:        Maria E. Cantor   Chiara Russo    Tom Malone Direct: 339-970-7536   Direct: 617-306-9137    Direct: 339-970-7558 Mobile:  617-680-9452   Mobile: 617-306-9137    Mobile: 339-223-8541 m.cantor@uniQure.com   c.russo@uniQure.com    t.malone@uniQure.com

Usando Yahoo accetti che Yahoo e i suoi partners utilizzino cookies per fini di personalizzazione e altre finalità